Spyglass Pharma Inc (SGP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,818 | N/A | -27,314 | -8,823 | -29,164 |
| Depreciation Amortization | 318 | N/A | 395 | 124 | 271 |
| Accounts receivable | -222 | N/A | 5 | -205 | N/A |
| Accounts payable and accrued liabilities | 953 | N/A | -471 | -372 | N/A |
| Other Working Capital | -1,751 | N/A | -113 | -1,472 | 1,338 |
| Other Operating Activity | 976 | 0 | 4,131 | 2,547 | 5,528 |
| Operating Cash Flow | $-13,544 | $N/A | $-23,367 | $-8,201 | $-22,027 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -991 | N/A | -12,000 | N/A | N/A |
| PPE Investments | -676 | N/A | -369 | -164 | -1,991 |
| Other Investing Activity | 0 | 0 | 0 | 0 | 24,252 |
| Investing Cash Flow | $-1,667 | $N/A | $-12,369 | $-164 | $22,261 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 160,480 | N/A | 150 | 100 | N/A |
| Common Stock Repurchased | N/A | N/A | -1,450 | N/A | N/A |
| Other Financing Activity | -2,725 | 0 | 126,774 | 49,996 | 185 |
| Financing Cash Flow | $157,755 | $N/A | $125,475 | $50,096 | $185 |
| Beginning Cash Position | 96,358 | N/A | 16,268 | 16,268 | 15,849 |
| End Cash Position | 238,902 | N/A | 106,007 | 57,999 | 16,268 |
| Net Cash Flow | $142,544 | $N/A | $89,739 | $41,731 | $419 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,544 | N/A | -23,367 | -8,201 | -22,027 |
| Capital Expenditure | -676 | N/A | -369 | -164 | N/A |
| Free Cash Flow | -14,220 | 0 | -23,735 | -8,365 | -22,027 |